|
Biotech Industry Overview
|
|
Global
|
Amount
|
Units
|
Year
|
Source
|
|
Public & Private Biotech Companies (US, Europe and Canada)
|
3,853
|
Companies
|
2010
|
E&Y
|
|
Public Biotech Companies
|
622
|
Companies
|
2010
|
E&Y
|
|
Biotech Revenues
|
80.6
|
Bil. US$
|
2010
|
E&Y
|
|
Total Pharmaceutical Sales, Worldwide
|
875.0
|
Bil. US$
|
2010
|
IMS
|
|
Total R&D Expenses, PhRMA Member Companies (Estimated)
|
49.4
|
Bil. US$
|
2010
|
PhRMA
|
|
Total R&D Expenses, All Pharmaceutical Companies
|
67.4
|
Bil. US$
|
2010
|
PhRMA
|
|
Area of Biotech Crops
|
148.0
|
Mil. Hectares
|
2010
|
ISAAA
|
|
U.S.
|
|
Public & Private Biotech Companies
|
1,703
|
Companies
|
2010
|
E&Y
|
|
Public Biotech Companies
|
315
|
Companies
|
2010
|
E&Y
|
|
Revenues
|
61.6
|
Bil. US$
|
2010
|
E&Y
|
|
Area of Biotech Crops
|
66.8
|
Mil. Hectares
|
2010
|
ISAAA
|
|
Prescription Drug Sales, Domestic
|
307.4
|
Bil. US$
|
2010
|
IMS
|
|
Number of FDA Approvals for New Drugs (NDAs) and Biologic License Applications (BLAs)
|
93
|
Approvals
|
2010
|
FDA
|
|
Number of Approvals for New Molecular Entities (NMEs) and BLAs
|
21
|
Approvals
|
2010
|
FDA
|
|
Patents Granted for "Multicellular Living Organisms & Unmodified Parts Thereof & Related Processes"
|
1,080
|
Patents
|
2010
|
USPTO
|
|
Medical Research Funding, NIH
|
31.2
|
Bil. US$
|
2010
|
NIH
|
|
Total Requested Budget for Biological Science Research, U.S. (NSF)
|
794.5
|
Mil. US$
|
2012
|
NSF
|
|
Mean Annual Salary for Biochemists & Biophysicists
|
86,580
|
US$
|
May-10
|
BLS
|
|
Employment of Biochemists and Biophysicists
|
22,800
|
Employees
|
May-10
|
BLS
|
|
Average Cost of Developing a Biologic Drug
|
1.2
|
Bil. US$
|
2005
|
Tufts
|
|
PhRMA1 Member Statistics, U.S.
|
|
Pharmaceutical Sales, Domestic
|
182.6
|
Bil. US$
|
2010
|
PhRMA
|
|
% Generic (by volume)
|
78.0
|
%
|
2010
|
PhRMA
|
|
Pharmaceutical Sales, Foreign2
|
108.8
|
Bil. US$
|
2010
|
PhRMA
|
|
Pharmaceutical R&D Spending, Domestic
|
37.4
|
Bil. US$
|
2010
|
PhRMA
|
|
as a Percentage of Domestic Sales
|
20.5
|
%
|
2010
|
PhRMA
|
|
Share of R&D Spending by Function:
|
|
Prehuman/Preclinical
|
25.2
|
%
|
2009
|
PhRMA
|
|
Phase I
|
8.1
|
%
|
2009
|
PhRMA
|
|
Phase II
|
15.3
|
%
|
2009
|
PhRMA
|
|
Phase III
|
35.1
|
%
|
2009
|
PhRMA
|
|
Approval
|
4.4
|
%
|
2009
|
PhRMA
|
|
Phase IV
|
11.4
|
%
|
2009
|
PhRMA
|
|
Uncategorized
|
0.4
|
%
|
2009
|
PhRMA
|
|
1 PhRMA = Pharmaceutical Research and Manufacturers Association, a group of leading pharmaceutical and biotechnology companies headquartered in the U.S. 2 Not including foreign divisions of foreign companies.
|
|
E&Y = Ernst & Young; IMS = IMS Health; ISAAA = International Service for the Acquisition of Agri-Biotech Applications; Tufts = Tufts University Center for the Study of Drug Development; FDA = U.S. Food & Drug Administration; USPTO = U.S. Patent & Trademark Office; NIH = U.S. National Institutes of Health; NSF = U.S. National Science Foundation; BLS = U.S. Bureau of Labor Statistics
|
|
|
|
|
|
|
|
Source: Plunkett Research, ® Ltd. Copyright © 2011, All Rights Reserved
|
|
www.plunkettresearch.com
|